Innovent Biologics, Inc. announces that the New Drug Application for mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, has been accepted by the Center for Drug Evaluation of the National Medical Products Administration of China, for chronic weight management in adults with obesity or overweight.
